Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8233043 | International Journal of Radiation Oncology*Biology*Physics | 2010 | 7 Pages |
Abstract
Our data suggest that lapatinib combined with fractionated radiotherapy may be useful against EGFR+ and HER2+ breast cancers and that inhibition of downstream signaling to ERK1/2 and AKT correlates with sensitization in EGFR+ and HER2+ cells, respectively.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Maria J. Ph.D., Randall J. M.D., Ph.D., J. Terese B.S., Eldon B.S., Chad A. M.D., Carolyn I. M.D., Janiel M. Ph.D.,